Factory Price Retatrutide CAS:2381089-83-2 for Research & Pharma | Custom Packaging
Name:Retatrutide
CAS:2381089-83-2
Molecular Formula:C₂₀₈H₃₁₈N₅₄O₆₃
Molecular Weight:~4536.5 g/mol
Sequence (Peptide Structure):A synthetic triple agonist peptide targeting:
- GIP (Glucose-dependent Insulinotropic Polypeptide) receptor
- GLP-1 (Glucagon-Like Peptide-1) receptor
- Glucagon receptor
Mechanism of Action:Simultaneously activates GIP, GLP-1, and glucagon receptors → enhances insulin secretion, reduces appetite, and promotes weight loss.
Current Status (2025):Under clinical trials (Phase 3) for type 2 diabetes and obesity.
Solubility Likely soluble in water (peptide-based, formulated for injection).
Storage Conditions Typically refrigerated (2–8°C) for stability.
Administration Route:Subcutaneous injection (similar to other GLP-1 analogs like semaglutide).
Key Features:
First-in-class triple agonist (GIP/GLP-1/Glucagon), potentially offering superior efficacy in weight loss and glycemic control compared to single or dual agonists (e.g., semaglutide, tirzepatide).
High molecular weight (~4.5 kDa) due to its peptide structure.
Complex synthesis (recombinant technology or solid-phase peptide synthesis required).
| Test Parameter | Acceptance Criteria | Test Method |
|---|
| Appearance | White to off-white, lyophilized powder or clear, colorless to slightly yellow solution | Visual inspection (USP <790>) |
| Identification | - HPLC retention time matches reference standard
- Mass spectrometry (MS): m/z ~4536.5 ± 2 Da | HPLC-UV/PDA
LC-MS/MS (USP <736>) |
| Purity (HPLC/Related Substances) | - Main peak: ≥ 95.0%
- Single impurity: ≤ 1.0%
- Total impurities: ≤ 5.0% | RP-HPLC (USP <621>) |
| Peptide Content (Assay) | 95.0% – 105.0% of label claim | Amino acid analysis (AAA) or UV absorbance |
| Water Content | ≤ 5.0% (for lyophilized form) | Karl Fischer titration (USP <921>) |
| Residual Solvents | - Acetonitrile: ≤ 0.041% (ICH Q3C Class 2)
- TFA: ≤ 0.1% | GC (USP <467>) |
| Microbial Limits | - Total aerobic count: ≤ 10 CFU/g
- Endotoxins: ≤ 5 EU/mg | USP <61>, <85> (LAL test) |
| Sterility | Sterile (for injectable formulation) | USP <71> (Membrane filtration) |
| pH | 6.0 – 8.0 (for solution) | Potentiometry (USP <791>) |
| Osmolality | 250 – 350 mOsm/kg (isotonic for injection) | Freezing point depression (USP <785>) |
| Subvisible Particles | - ≥ 10 µm: ≤ 6,000 particles/container
- ≥ 25 µm: ≤ 600 particles/container | USP <788> (Light obscuration) |
| Peptide Sequence | Confirmed by N-terminal sequencing (Edman degradation) or LC-MS/MS | Edman degradation / LC-MS/MS |
| Secondary Structure | Consistent with reference standard (e.g., α-helix content by CD spectroscopy) | Circular Dichroism (CD) |
China
